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Abstract
A promising strategy to accelerate joint implant integration and reduce recovery time and failure
rates is to deliver a combination of certain growth factors to the integration site. There is a need to
control the quantity of growth factors delivered at different times during the healing process to
maximize efficacy. Polyelectrolyte multilayer (PEM) films, built using the layer-by-layer (LbL)
technique, are attractive for releasing controlled amounts of potent growth factors over a sustained
period. Here, we present PEM films that sequester physiological amounts of osteogenic rhBMP-2
(recombinant human bone morphogenetic protein - 2) and angiogenic rhVEGF165 (recombinant
human vascular endothelial growth factor) in different ratios in a degradable [poly(β-amino ester)/
polyanion/growth factor/ polyanion] LbL tetralayer repeat architecture where the biologic load
scaled linearly with the number of tetralayers. No burst release of either growth factor was
observed as the films degraded. The release of rhBMP-2 was sustained over a period of 2 weeks,
while rhVEGF165 eluted from the film over the first 8 days. Both growth factors retained their
efficacy, as quantified with relevant in vitro assays. rhBMP-2 initiated a dose dependent
differentiation cascade in MC3T3-E1S4 pre-osteoblasts while rhVEGF165 upregulated HUVEC
proliferation, and accelerated closure of a scratch in HUVEC cell cultures in a dose dependent
manner. In vivo, the mineral density of ectopic bone formed de novo by rhBMP-2/rhVEGF165
PEM films was approximately 33% higher than when only rhBMP-2 was introduced, with a
higher trabecular thickness, which would indicate a decrease in the risk of osteoporotic fracture.
Bone formed throughout the scaffold when both growth factors were released, which suggests
more complete remodeling due to an increased local vascular network. This study demonstrates a
promising approach to delivering precise doses of multiple growth factors for a variety of implant
applications where control over spatial and temporal release profile of the biologic is desired.
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1. Introduction
Approximately 10% of total hip prostheses (THP) are revised within 10 years after the
procedure due to loosening of the implant [1], almost entirely because of the failure of
fixation in cases of aseptic loosening [2] . In order to engineer a successful implant, it is
necessary to address the bone as a highly vascularized tissue where a multistep process
involving migration, proliferation, differentiation, and activation of several cell types is
necessary for integrating the implant with the bone tissue [3]. Several growth factors have
been implicated in this process [4], and bone morphogenetic proteins (BMP) have been
shown to be some of the most potent bone tissue-forming proteins known amongst the
growth factors investigated for bone tissue growth, and are the only growth factors capable
of directly inducing de novo bone formation [5]. Recombinant human BMP-2 (rhBMP-2) is
an osteogenic growth factor used extensively in both ectopic and orthotopic sites for bone
generation; it has been demonstrated in various animal models for healing fracture sites and
femur defects, such as in rats [6, 7], rabbits [8] and sheep [9], and is an approved product for
use on humans in lumbar spine fusion [10] . The benefits of release of growth factors such
as rhBMP-2 include rapid healing of tissue around the implant [11] and more complete bone
remodeling over shorter time periods [12]. Recombinant human vascular endothelial growth
factor (rhVEGF) is an angiogenic factor critical for both intramembranous and endochondral
bone formation [3]. Angiogenesis is required for most tissues to develop and is a critical
component of virtually all tissue-engineering strategies and the growth process and
restructuring of bone tissue is greatly enhanced by increased vascularization [13] and the
introduction of rhVEGF has been shown to enhance bone formation [14] through the
development of the localized vascular system and increased blood flow. rhVEGF has been
shown to act synergistically with rhBMP-2 to increase the growth of bone tissue [15].
Localized introduction of such growth factors has been demonstrated to greatly enhance
bone tissue regeneration [16, 17]. Hence there is a therapeutic advantage to introducing
growth factors from the surface of implants during the healing process.
The delivery of growth factors in vivo presents many complex challenges [18]. Growth
factors, specifically rhBMP-2 and rhVEGF have been delivered therapeutically for bone
regeneration applications using a variety of methods, including bolus injection [19],
biodegradable polymers and hydrogels [7, 20, 21] with mixed results [22]. In cases where
beneficial effects were observed, large doses of the growth factors were required (from 12
μg up to 60 mg of growth factor per gram of carrier). This raises concerns regarding the
safety, cost and effective delivery of these supraphysiological amounts of recombinant
proteins. Control over the amount of growth factor delivered is critical in bone tissue healing
applications, where an excess of rhBMP-2 may lead to undesirable incidences of hematoma,
ectopic bone formation and osteoclast activation with transiently elevated bone resorption
[23]. From a delivery perspective, traditional polymer formulation techniques also have the
potential to denature the protein molecules at high temperature, by exposure to unfavorable
solvents or through the development of a low pH environment [24]. In addition, these
systems are not easily coated onto complex geometries of implants in a conformal manner.
Direct injection of growth factor to a fracture site would lead to the immediate breakdown
and resorption of the protein before it could begin to exhibit desired results as the growth
factor must be sustained at a minimal dose level over prolonged time periods of several
weeks to be effective [25]. The ratio and timing of rhBMP-2 and rhVEGF delivered may be
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critical to applications involving bone tissue integration [3]; beneficial effects have been
observed when rhVEGF is present in quantities of half or less than rhBMP during the first
few days or weeks [26], i.e. the consolidation phase, and may even be introduced prior to the
introduction of rhBMP-2 [27]. rhVEGF dosage must be tightly controlled, as excess
amounts of rhVEGF from extended release can actually inhibit osteogenesis, cause severe
vascular leakage and hypotension [28].
Towards addressing a lack of delivery systems where tunable control is necessary for the
delivery of these potent growth factors [29], our primary goal was to develop a thin
hydrolytically degradable coating that would incorporate controlled amounts of both
rhVEGF and rhBMP-2, releasing them over varying periods of time with a corresponding
dose dependent effect on endothelial and preosteoblast cells respectively. A suitable delivery
platform would exhibit a quick release of rhVEGF and a more sustained release of
rhBMP-2. Polyelectrolyte multilayer films fabricated using the layer-by-layer (LbL)
assembly [30], in which a charged substrate was alternately dipped in positively and
negatively charged polymer baths to build nanolayered thin films has been explored as a
means to successfully release various drugs and small molecules from surfaces as well as
developing LbL coatings for tissue regeneration by our group [31-35] as well as others
[36-41]. The LbL assembly method is unique in its ability to sequester desired
concentrations of biologic drugs for controlled local delivery using room temperature and
mild aqueous conditions that preserve fragile protein activity. Orthopedic implant surfaces
are a compelling application as the polyelectrolyte multilayer approach can have direct and
immediate benefit in this area due to the need for sequential and controlled delivery of
several therapeutic systems. Introduction of more than one growth factor in vivo would
initiate the different cellular cascade necessary for robust implant integration using a
powerful LbL approach to generate blends of dual growth factors that can yield idealized
release behavior.
2. Materials and Methods
2.1. Materials
Poly (β-aminoester) 2, hereafter called Poly2, was synthesized as previously described [42].
Poly(acrylic acid)(PAA, 306215, Mν = 1.25MDa), 3M concentrated sodium acetate buffer
(S7899, pH 5.2) and penicillin/ streptomycin solution were purchased from Sigma Aldrich
(St.Louis, MO). Recombinant human BMP-2 (rhBMP-2, 4577) and recombinant human
vascular endothelial growth factor C (rhVEGF-C, 165 amino acids excluding His tags at the
end, 4633) was obtained from Biovision Inc. (South San Francisco, CA). rhBMP-2 ELISA
kits were obtained from Peprotech Inc. (Rocky Hill, NJ). 10x Phosphate buffer Saline (PBS)
was obtained from Invitrogen (Carlsbad, CA). Chondroitin sulfate sodium salt (Mn = 60000)
was obtained from VWR Scientific (Edison NJ).
2.2. Preparation of polyelectrolyte solutions
Poly2 dipping solutions were 2 mg/mL in 25 mM sodium acetate buffer. Dipping solutions
containing PAA and chondroitin sulfate were prepared at 2 mg/mL in 100mM sodium
acetate buffer and pH-adjusted to 5.0 with 1.0M sodium hydroxide solution. rhBMP-2 and
rhVEGF165 dipping solutions were 40 μg/ml in 100 mM sodium acetate buffer. Poly2, PAA
and chondroitin sulfate dipping solutions were replaced every 24 hours. rhBMP-2 and
rhVEGF165 dipping solutions were replenished every 24 hours by adding 40 μg/mL of
growth factor to their respective pre-existing solutions. All solutions were prepared with
water from a Milli-Q Plus unit (Bedford, MA) at 18.2 MΩ.
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2.3. Polyelectrolyte multilayer film construction
Integra-ls® (Plainsboro, NJ) macroporous polycaprolactone/β-tricalcium phosphate (50wt%
PCL/50wt% β-TCP) waffle cylinder scaffold, with diameter = 10mm and height = 2.5mm
were cut in half using a razor blade and plasma etched with room air using a Harrick
PDC-32G plasma cleaner on high RF power for 1 min and immediately immersed in Poly2
solution. First, rhBMP-2 nanolayered films were fabricated on this scaffold with a Carl Zeiss
HMS programmable slide stainer with the following dipping protocol: 5 min in Poly2
solution, 3 washes (10, 20, 30 s), 5 min in PAA solution, 3 washes (10, 20, 30 s), 10 min in
rhBMP-2 solution, 1 wash (10 s) and 5 min in PAA solution with 3 washes (10, 20, 30 s).
This cycle was repeated to achieve 40, 80, 100 and 120 tetralayer films. Dipped scaffolds
were allowed to dry for 48 hours at 4°C. Next, rhVEGF165 nanolayered films were then
fabricated on the scaffolds using the same dipping protocol to achieve 20, 30, 40, 50 and 80
tetralayer films with the rhBMP-2 dipping solution swapped for the rhVEGF165 dipping
solution and the PAA replaced with chondroitin sulfate. Concurrently, controls with single
growth factor films were also fabricated. The final product was stored at 4°C until released
or implanted.
2.4. Release characterization
Growth factor coated film coated scaffolds were released at 37°C into 1 mL of 1x PBS in
1.7 ml centrifuge tubes (VWR Scientific, Edison, NJ). At a series of pre-determined time
points, scaffolds were transferred into new centrifuge tubes containing fresh 1ml 1x PBS.
The previous centrifuge tubes along with the 1x PBS, were frozen down and stored at
−20°C. Samples were analyzed using ELISA development kits according to manufacturer
instructions. Release samples from consecutive time points were then combined and used in
cellular assays (see below).
2.5. Cell culture
To test the efficacy of the growth factors released from the LbL films, a number of in vitro
tests were performed to quantify and visualize the effect of growth factor on a cell line with
a physiological response to the growth factor. rhBMP-2 initiates the differentiation of pre-
osteoblast cell line MC3T3-E1 into bone. rhVEGF165 induces proliferation and migration in
HUVEC’s. ). Each condition was repeat 3 times in triplicate (n=3).
2.5.1 rhBMP-2 activity assays using MC3T3-E1 pre-osteoblast cell line—
MC3T3-E1 Subclone 4 cells were grown in α-MEM, supplemented with 10% FBS, and 1%
of antibiotic and anti mycotic solution (containing penicillin, streptomycin and amphotericin
B) in a humidified incubator (37°C; 5% CO2 in air). Culture medium was replenished every
2-3 days and cells were sub cultured when near 100% confluence with the use of 0.05%
trypsin-EDTA. All cells used in these studies were less than passage number 12. MC3T3-E1
cells were seeded at 10,000 cells/well and allowed to grow to confluency in 24 well plates
(visualization and quantification) in 0.5 ml of growth medium. Cells were cultured under
different experimental conditions: (1) growth medium, (2) differentiation medium (growth
medium supplemented with 50 mg/ml L-ascorbic acid and 10 mM b-glycerol phosphate), (3)
differentiation medium supplemented with PEM released solution containing rhBMP-2 and
rhVEGF165. Release samples from consecutive days were combined and the cell culture
media was changed every two days until analysis for alkaline phosphatase or alizarin red as
described below.
Alkaline phosphatase activity assay: Alkaline phosphatase (ALP) activity was determined
on day 5 after the initiation of MC3T3-E1 osteogenic differentation by quantitation of the
enzyme activity. Cells were rinsed 2x with PBS without Ca2+ and Mg2+ and fixed in 8%
paraformaldehyde for 10 min at room temperature. 0.1% triton in PBS was added to the
Shah et al. Page 4
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
fixed cells and then frozen at 80°C for one freeze-thaw cycle. Cell lysates were transferred
to an eppendorf tube, centrifuged at 15,000g for 3 min at 4°C, and the supernatant was
collected. 50 μl of lysate was incubated with 150 μL of pNPP solution for 30 min at 37°C.
The reaction was terminated with 0.1 M NaOH and ALP activity read on a plate reader at
405 nm. The ALP activity measurements were normalized to total protein determined by
BCA assay.
Alizarin red S differentiation assays: After 14 days of exposure to different formulations
of the release medium, MC3T3-E1 cells were assayed for calcium deposition using Alizarin
red S (ARS). Cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min.
After three rinses of 5 min in distilled water, ARS stain solution (2% ARS in distilled water
pH balanced to 4.1 with 10% ammonium hydroxide) was incubated with cells for 20 min at
room temperature. Cells were then washed in distilled water 4 times for 5 min each. The
ARS stained cultures were imaged with phase contrast microscopy. The ARS stain was
quantified using a previously published protocol [43]. The ARS stained cultures were
incubated in 10% acetic acid for 30 min at room temperature and then the cell layers were
disrupted by the use a pipette tip. The cell suspensions were transferred to a microcentrifuge
tube, vortexed for 30 s, paraffin wrapped and heated at 85 °C for 10 min. After transferring
to ice for 5 min, the tubes were centrifuged at 16,000g for 15 min and pH balanced with
10% ammonium hydroxide to pH 4.1-4.5. Triplicates with growth and differentiation
medium controls were read on a 96-well plate with black sides and a clear bottom at 405
nm.
2.5.2 rhVEGF165 activity assays using Human Umbilical Vein Endothelial Cells
(HUVEC) cell line—Release media was pooled and diluted 1:1 with HUVEC media
(without rhVEGF). The normalized rhVEGF165 dose per milligram of scaffold was
calculated, aliquoted and topped up with HUVEC media (without VEGF) for a total volume
of 300 μl per well for proliferation assays and 2.5ml per well for migration assays.
HUVEC proliferation assay: 1000 HUVEC’s were suspended in 300 μl of growth media
and dispensed in each well of a 96 well plate (quantification) in 0.3 ml of growth medium.
Cells were allowed to establish for 24 hours. HUVEC growth media was carefully removed
using a pipettor without disturbing the cell layer. The combination of release and HUVEC
media, was then added to the wells. Cells were allowed to proliferate for 48 hours and
labeled with 10 μM bromodeoxyuridine (BrdU) kit for another 2 hours. Incorporation of
BrdU into DNA was detected using an anti-BrdU peroxidase-conjugated antibody and a
soluble peroxidase substrate (3,3′-5,5′-tetramethylbenzidine). The absorbance was measured
at 450 nm with a 595 nm reference wavelength according to the protocol for BrdU
Proliferation Assay, (Roche Diagnostics, Mannheim, Germany).
HUVEC migration assay: Confluent HUVEC monolayers in 24 well plates (Corning/
Costar, Cambridge, MA) were “scratch” wounded using the tip of a universal blue pipette
tip and rinsed with PBS. The HUVEC/Release media cocktail from different experimental
conditions was pipetted into the plate. Cells were imaged under phase contrast microscope
(Axiovert® 200 inverted microscope, Carl Zeiss, NY) immediately after adding media.
HUVEC media with lacking rhVEGF was used as the control. Cells were incubated for 8
hours and the distance migrated by the cells. Cells were labeled with 1.5 μm Calcein AM
Fluorescent Dye (354217, BD Biosciences, CA) for 30 min. The media and dye were
aspirated and washed thrice with 1x PBS. Cells were then fixed with 8% paraformaldehyde
and imaged under fluorescence (485 nm excitation 530 nm emission) at 20x magnification.
The size of the scratch before and after 8 hours was measured using Axiovision® 4.5
software and the difference computed as the distance migrated by the cells.
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2.5.3 In vivo evaluation of LbL films—All animal work was performed in accordance
with protocols approved by the Committee on Animal Care at the Massachusetts Institute of
Technology. A set of eight 100 tetralayer rhBMP-2 films (corresponding to a 6μg total
scaffold load), eight 100 tetralayer rhBMP-2 films with an 80 tetralayer rhVEGF165 film on
top (corresponding to a 6μg rhBMP-2 and 4μg rhVEGF165 total scaffold load) and eight 100
tetralayer Poly2/PAA bilayer films were built as implants. Sixteen 350-400 g male Sprague
Dawley rats were given preoperative analgesics (1 mg/kg meloxicam and 0.05 mg/kg
buprenex), and intraoperative anesthesia via 1-3% isofurane in oxygen. The right hind limb
of each animal was shaved, cleaned with alcohol and povidone iodine solutions, and sterile
drapes were placed around the surgical area. A 2 cm longitudinal incision, centered at the
midshaft of the femur, was made laterally along the hind limb. A pocket made in the
quadriceps muscle mass by blunt dissection anterior to the iliotibial band. LbL-coated PCL/
βTCP scaffold was inserted into the intramuscular pocket, and wounds were closed
progressively with three layers of sutures (muscle, subcutaneous, and dermal layers). Each
hindlimb was implanted with either a control scaffold [P2/PAA]100, a rhBMP-2 scaffold
[P2/PAA/rhBMP-2/PAA]100 or a scaffold with rhBMP-2/rhVEGF165 combination film
[Poly2/PAA/rhBMP-2/PAA]100[Poly2/Chondroitin sulfate/rhVEGF165/Chondroitin
sulfate]80 Postoperatively, rats were treated with buprenex and meloxicam until signs of
distress dissipated. Rats were housed in separate cages with free access to food and water.
At four and eight week time points, four rats from each group were sacrificed and the
implants retrieved for analysis as described below.
Micro-computed tomography (MicroCT) analysis: Excised samples were immediately
placed in 10% neutral buffered formalin and imaged with MicroCT (eXplore Locus, GE
Medical Systems, London, Ontario) at a resolution of 27 μm with proprietary software
included with the system (EVS Evolver, GE Medical Systems, Fairfield, CT). The scanning
protocol was performed with a 2000 ms shutter speed, 1 x 1 binning, at X-ray tube
parameters 80 kV and 450 mA. Four hundred images were taken at incremental angles, and
rendered 3D images were reconstructed with the Reconstruction Utility and analyzed using
MicroView (GE Healthcare, Fairfield, CT). Threshold values were chosen by visual
inspection and kept constant across 1 month or 2 month data sets. Three independent regions
of interest (ROIs) were chosen per sample, and the bone analysis tool was used to measure
bone mineral density and stereology measurements of each sample. Three dimensional
representations of bone formation and two dimensional digital slices through the samples
were also taken for qualitative comparison. Each sample was measured in triplicate for each
set of data.
Histological analysis: After 24 h in 10% formalin, tissues were transferred to solutions of
70% ethanol prior to decalcification. Tissues were decalcified for 5 days in a solution of
15% EDTA and 10% sodium citrate buffer, pH 7.2 at 4°C under continuous stirring. Tissues
were then serially sectioned, routinely processed, and embedded in paraffin. Microscope
sections (4 μm) were stained with hematoxylin and eosin (H&E), Alcian Blue, and Masson’s
trichrome stains.
3. Results and Discussion
3.1 Fabricating a dual growth factor releasing layer-by-layer system
Both rhBMP-2 and rhVEGF165 are homodimeric proteins which have a similar pI of about
8.5; the non-glycosylated forms have a molecular weight of about 30 kDa and 38.2 kDa
respectively. Under conditions of acidic and physiological pH, both proteins are expected to
be positively charged. Hence, for the layer-by-layer film assembly, we used a tetralayer
architecture with 1) Poly2, a synthetic poly(β-aminoester); 2) a biocompatible polyanion
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(PAA or Chondroitin sulfate); 3) a growth factor (either rhBMP-2 of rhVEGF165) and 4) a
polyanion for charge reversal (Fig. 1.).
In order to successfully release growth factor under physiological conditions, we chose
Poly2 which is a hydrolytically degradable member of the poly (β-aminoester) (PBAE)
family, which has been extensively studied in gene therapy [44] applications and used for
PEM fabrication for various delivery applications from multilayer films with appropriate
architectures [45]. Under neutral to acidic pH conditions of film fabrication, Poly2 is stable
and the amines present along the backbone of Poly2 are protonated, yielding the positive
charge necessary for electrostatic LbL systems. We anticipated that films constructed with
PAA as the alternating polyanion would yield more highly ionically crosslinked films
relative to chondroitin sulfate, as PAA exhibits a higher charge density. Such films should
result in a more sustained release profile of rhBMP-2. An important phase of wound healing
involves the secretion of glycosaminoglycans by fibroblast cells to form a hydrophilic
matrix suitable for remodeling while healing. Chondroitin sulfate has been extensively
investigated for wound dressing applications [46] due to its biocompatibility, non-
immunogenicity and pliability. Thus it was the polyanion of choice for fabricating the
rhVEGF165 PEM films. Films with tetralayer repeat units were fabricated, where the
tetralayers containing rhBMP-2 were adsorbed first, and rhVEGF165 layers were adsorbed
on top (Figure 1). We anticipated releasing growth factor from the surface of implants,
where more rhVEGF165 would be released initially for stimulating proliferation of blood
vessels in vivo, followed by more rhBMP-2, which would initiate the differentiation cascade
leading to the formation of new bone.
Hydrogel based dual growth factor releasing systems have been reported [7], where
components are fabricated separately and do not offer the convenience of conformal coating.
Here, LbL was used to conformally coat the complex geometries of an osteoconductive
macroporous polycaprolactone/β-tricalcium phosphate (50wt% PCL/50wt% β-TCP) waffle
cylinder scaffold, with diameter = 10mm and height = 2.5mm. The three dimensional,
porous scaffold was used for in vitro and in vivo testing as a model implant (Figure 1.). The
choice of scaffold was governed by the following factors: (i) PCL is a biologically inert,
biocompatible FDA approved material, (ii) βTCP is an osteoconductive material and
typically both an osteoinductive agent, such as rhBMP-2, and an osteoconductive
microenvironment are necessary for ectopic bone formation (iii) the total drug load scales
with film surface area, allowing for a greater load per volume in a macroporous three
dimensional substrate compared with a flat film [35].
3.2 In vitro kinetics of dual growth factor releasing films
While the precise growth factor dose required would depend on the specific orthopedic
application, [Poly2/PAA/rhBMP-2/PAA]x[Poly2/Chondroitin sulfate/rhVEGF165/
Chondroitin sulfate]y films were constructed with the aim of demonstrating that this system
could be tuned for specific applications involving bone regeneration and that the released
growth factors demonstrate a dose response behavior. Release from the film was normalized
to 1 milligram of scaffold weight, to provide a basis for comparison.
We tuned our system to demonstrate a control over total growth factor loading. Release of
growth factors from the film occurs with a pH shift from pH 5.0 at dipping conditions to
physiological pH 7.4 in 1x PBS, due to a combination of destabilization and charge
imbalance in the films and from hydrolytic degradation of the Poly-2 backbone.
Approximately one-third of the rhBMP-2 and two-thirds of the rhVEGF165 was released
after three days. While both growth factors begin release immediately upon immersion, the
release profile for rhBMP-2 indicates that it takes a longer time to elute completely from the
film than rhVEGF165. The amount of growth factor released from single growth factor films
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(Fig. 2. A, B) and dual growth factor films (Fig. 2. C, D, E, F) is comparable, and in all
cases, indicate that amounts of growth factor for each component can be independently
tuned to yield a clear increase in loading with number of layers. This is an important
capability for delivery film design that is not always readily attained with multilayer
formulations; it indicates that the growth factor does not leach out of the film by diffusion
into the dipping solution when a different growth factor is introduced. Electrostatic
interactions between the growth factor and surrounding polymer chains in the film prevent it
from diffusing out or being exchanged out during film assembly. Loading of rhBMP-2 and
rhVEGF scaled linearly with tetralayer number with 4.50 ± 0.14 ng (R2 165 = 0.93) and 3.72
± 0.080 ng (R2 = 0.96) of rhBMP-2 and rhVEGF165 respectively per tetralayer per milligram
of scaffold (n = 3). In these films, total rhBMP-2 and total rhVEGF165 incorporation ranged
from 250 and 600 ng/mg scaffold weight and 80 to 200 ng/mg scaffold weight, respectively,
as a function of number of layers. A broad range of protein incorporation in films has been
previously reported from 2D substrates, from 5 ng/cm2 upto 650 μg/cm2 [34, 47]. The
release profiles in Figure 2 are characteristic of surface erosion behavior. The release profile
in Fig. 2A indicates gradual linear release as the rhBMP-2 is completely eluted. We would
expect the film would undergo bulk erosion if the water permeates into the LbL films faster
than the rate of hydrolytic degradation of Poly2 and surface erosion if the rate of permeation
is slower. The dominance of surface erosion is due to the prolonged half-life of Poly2
conferred by the presence of a hydrophobic region near the ester bond and a consequent
decrease in water attack on the bond, hence a slower degradation rate of the polymer. Our
previous work has demonstrated that a related PBAE (Poly1), with a shorter alkyl chain near
the ester bonds, releases a comparable cargo much faster [34]. In case of the single and dual
growth factor releasing films, rhBMP-2 release is consistent across the different groups (x =
40, 80, 100, 120) at 27.4 ± 8.38% per day averaged over the first 2 days and 5.3 ± 0.34% per
day until the end of release. In single growth factor rhVEGF165 films, release is consistent
across the different groups (y = 20, 30, 40, 50), at 20 ± 0.07% per day averaged over the first
5 days, after which there is no detectable release. For dual growth factor films, it is
interesting to note that the amount of rhVEGF165 released drops to 15 ± 1.42% per day
averaged over the first 5 days and 3.05 ± 0.96% per day until the end of release. It is likely
that interdiffusion occurs with both growth factors during film assembly, leading to a mixing
of BMP-2 and VEGF with in the film matrix, although a gradient of BMP-2 may still remain
in the bottom layers of the film, leading to more extended release. Interdiffusion of
components in polyelectrolyte multilayers has been reported for similar systems [48, 49].
3.3 In vitro rhBMP-2 activity assay
To study the rhBMP-2 dose dependent behavior of MC3T3-E1 cells in vitro, we exposed the
cells to different formulations – growth media, differentiation media (growth media
supplement with L-ascorbic acid and β-glycerolphosphate) and release media with the
rhBMP-2 load normalized to 1 milligram of scaffold weight. Alkaline phosphatase (AP)
serves as a standard early marker of induction of new bone differentiation from progenitor
cells. In Figure 3A and 3B, the AP signal is dose dependent to the amount of rhBMP-2
exposed to the cells (p<0.05). In Figure 3C, AP signal is the same across the different
formulations, as expected as the amount of rhBMP-2 in the formulation is the same. Alizarin
red (AR) stains for calcium deposits and allows for its visualization and quantification. AR
staining was performed 14 days after exposure to the different formulations. In Figures 3D,
3E, 3F, staining of Alizarin Red confirms osteoblast differentiation to a mature bone
phenotype from rhBMP-2 exposure. Staining was quantified and observed to be dose
dependent when the dose of rhBMP-2 was varied (Figures 3D, 3E) (p<0.05) and the
intensity of the stain was the same when the rhBMP-2 dose was constant (Figure 3F).
Interestingly, the staining was more diffuse when rhVEGF165 and chondroitin sulfate was
part of the formulation (Fig. 3E, 3F). We have observed in our previous work [35] that the
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presence of chondroitin sulfate, a glycosaminoglycan, allows for a more even distribution of
rhBMP-2 in culture resulting in a more diffuse stain. In all cases, the formulations
significantly outperformed the differentiation induced by the growth and differentiation
media.
3.4 In vitro rhVEGF165 activity assay
HUVEC’s have been shown to respond to rhVEGF165 concentration in a dose dependent
manner at low concentrations of rhVEGF165. Complimentary to these findings, we
demonstrated that the rhVEGF165 released from the LbL films was active and induced dose
dependent proliferation and migration of HUVEC’s.
Proliferation of HUVEC’s was measured using BrdU, a synthetic nucleoside that is an
analogue of thymidine and can be incorporated into the newly synthesized DNA of
replicating cells substituting for thymidine during DNA replication. Cells were seeded at a
low density to prevent wells from reaching confluency within the period of this study. Cells
exposed to formulations were the rhVEGF165 load was changed demonstrated a dose
response behavior which was statistically significant (Figure 4A, 4B) (p < 0.05). Dose
response to linear increases in the number of tetralayers was also linear (R2 = 0.99) which is
consistent with observations elsewhere [50]. The degree of change in proliferation was
statistically insignificant when the rhVEGF165 load was kept constant (Figure 4C) (p>0.05).
Migration of HUVEC’s was measured as the difference in the average size of the scratch
made in a confluent monolayer of cells before and after incubating the cells with different
formulations of release medium. Here too, a dose response behavior was observed with the
scratch size decreasing linearly as a function of rhVEGF165 load (R2 = 0.99).
3.5 In vivo evaluation of LbL films using intramuscular bone formation model
We demonstrated the efficacy of the LbL coated implants in vivo. Consistent with our
previous work [35], the osteoconductive scaffold and the osteoinductive rhBMP-2 formed
bone at an intramuscular ectopic site. Adding an angiogenic factor accelerated the
maturation of ectopic bone. Microcomputed tomography (microCT) images at four and nine
week time points showed large bone deposits created in response to rhBMP-2 LbL films.
Growth factor coated implants (Figure 6) showed new plate-like bone trabeculae that
progressively increased in thickness from four to nine weeks. Quantification of the bone
mineral density (BMD) from microCT images demonstrated an increase of 28 ± 4.59% and
32 ± 2.73% at 4 and 9 weeks respectively (p < 0.001) for the scaffolds coated with
rhBMP-2/rhVEGF165 over the scaffolds coated with just rhBMP-2. In contrast, no bone was
formed in scaffolds coated with LbL films lacking growth factor.
The bone formation was restricted to the periphery of the scaffold when just rhBMP-2 was
used. Over the initial 4 week time period, a greater amount of bone was present deep within
scaffold when both rhBMP-2 and rhVEGF165 were released from the scaffold surface as
measured by bone mineral density on the scaffold surface and the interior of the scaffold
(Fig. 6A, B). Interior bone mineral density increased by 27 ± 7.1% in scaffolds with the
combination growth factors, while the increase in BMP-2 eluting films was statistically
insignificant. Trabecular thickness of the peripheral bone formed by the rhBMP-2/
rhVEGF165 combination scaffolds, was found to be 3 fold and 4.5 fold greater than the bone
formed by the BMP-2 scaffold at 4 and 9 weeks respectively (Fig. 6C).
Histological sections of excised implants from the rat femur (Fig.7.) showed active bone
formation and remodeling with osteocytes and cement lines where new bone is laid down by
differentiating osteoblasts within scaffolds releasing either rhBMP-2 or the combination of
rhVEGF165 and rhBMP-2 (Fig. 7E-7L). Bone marrow with maturing trilineage
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hematopoiesis was occasionally observed (Fig. 7G). Bone was deposited on the interior
surface of the scaffold, and was restricted to the area of the implant (Fig 7F, 7H, 7J, 7L).
This is important, as it demonstrates that the system was able to control bone formation at an
ectopic site. At 4 weeks, spicules of trabecular bone were observed throughout the scaffold
in combination growth factor releasing films, whereas the spicules were restricted to the
periphery in single growth factor rhBMP-2 films. In both cases, mature lamellar bone was
observed from 4 to 9 weeks as visualized by aligned collagen fibrils that are birefringent
under polarized light. Interestingly, a large number of hematopoietic cells were observed
around areas of mature lamellar bone at 9 weeks along with adipocytes, recapitulating the
fatty marrow architecture and suggesting a high level of tissue maturation. Consistent with
endochondral bone formation, a cartilage intermediate is visible in the bone tissue induced
by growth factor PEM films (Fig. 7F, J) which is progressively replaced with bone which
extends throughout the scaffold only when rhVEGF165 is present. The de novo
recapitulation of a more complete bone architecture precipitated by PEM mediated release
of dual growth factor rhVEGF165 and rhBMP-2 from the scaffold surface, suggests that
there may be a greater initial concurrent vascularization process which mediates introduction
of more cells in the interior on the scaffolds; none of the aforementioned biological
processes is present in LbL scaffolds lacking BMP-2.
4. Conclusions
The ability to regulate the local availability of precise amounts of growth factors is a potent
tool for bone tissue engineering where the differentiation of many stem cell types typically
requires the action of several growth factors at distinct stages. The utility of rhBMP-2 and
rhVEGF has been well documented in mediating interactions between host tissue and
implant. We have presented polyelectrolyte multilayer films that are able to deliver
independently tunable nanogram scale physiological amounts of active rhBMP-2 and
rhVEGF over different timeframes and induce a corresponding dose response on
physiologically responsive cell lines. It is important to note that the dose response behavior
is restricted to micromolar scale quantities of growth factors, and we were able to
demonstrate control at these levels using sustained release obtained with hydrolytic
degradation. PEM films on an osteoconductive scaffold induced ectopic bone formation in
the intramuscular region of a rat femur. The delivery of two growth factors - rhBMP-2 and
rhVEGF - changed the microenvironment significantly compared to single growth factor
rhBMP-2 such that the trabecular bone formed throughout the scaffold and was more
continuous and matured faster compared to single growth factor BMP-2 delivery. The ease
of fabrication of this system makes it highly flexible; it can be applied to a wide variety of
tissue engineering applications, including PEM films to treat diabetic ulcers, lumbar spine
fusion and fracture healing. These results are an important step toward developing a system
capable of multiple biologic drug delivery in vivo, and offering successful and long lasting
joint replacement wound healing and repair. Furthermore, the general demonstration of dual
controlled growth factor release from a thin film coating platform is a significant advance
for numerous applications from implant coatings to tissue engineering.
Acknowledgments
This work was funded by the National Institutes of Health, National Institute of Aging (5R01AG029601-04). The
authors acknowledge the assistance provided by Catrina Wong and Alison Hayward, DVM (support staff, Division
of Comparative Medicine, MIT) for care, handling and anesthesia of animals. The authors greatly appreciate the use
of equipment available at the Institute for Soldier Nanotechnologies (ISN) and MRSEC Shared Facilities supported
by the National Science Foundation (DMR-0213282) at MIT, and the support provided by the staff in the
microscopy, histology and animal imaging core facilities at the Swanson Biotechnology Center in the David H.
Koch Institute for Integrative Cancer Research supported by the National Institutes of Health, National Cancer
Institute (2P30CA014051-39). The authors also acknowledge Integra Life Sciences (Plainsboro, NJ) and James
Serdy (MIT) for providing the scaffolds used in this study.
Shah et al. Page 10
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
References
1. Ince A, Rupp J, Frommelt L, Katzer A, Gille J, Lohr JF. Is “aseptic” loosening of the prosthetic cup
after total hip replacement due to nonculturable bacterial pathogens in patients with low-grade
infection? Clin Infect Dis. 2004; 39(11):1599–1603. [PubMed: 15578358]
2. Harris WH, Sledge CB. Total hip and total knee replacement. N Engl J Med. 1990; 323(11):725–
731. [PubMed: 2201916]
3. Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr. Ferrara N, et al. Vascular endothelial growth
factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S
A. 2002; 99(15):9656–9661. [PubMed: 12118119]
4. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology
and clinical applications. J Bone Joint Surg Am. 2002; 84-A(6):1032–1044. [PubMed: 12063342]
5. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of
bone formation: molecular clones and activities. Science. 1988; 242(4885):1528–1534. [PubMed:
3201241]
6. Patel ZS, Young S, Tabata Y, Jansen JA, Wong ME, Mikos AG. Dual delivery of an angiogenic and
an osteogenic growth factor for bone regeneration in a critical size defect model. Bone. 2008; 43(5):
931–940. [PubMed: 18675385]
7. Kempen DH, Lu L, Heijink A, Hefferan TE, Creemers LB, Maran A, et al. Effect of local sequential
VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials. 2009;
30(14):2816–2825. [PubMed: 19232714]
8. Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2
(rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am.
1997; 79(10):1452–1463. [PubMed: 9378731]
9. Gerhart TN, Kirker-Head CA, Kriz MJ, Holtrop ME, Hennig GE, Hipp J, et al. Healing segmental
femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Relat
Res. 1993; (293):317–326. [PubMed: 8339499]
10. Uludag H, Gao TJ, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: factors
contributing to protein retention at an application site. J Bone Joint Surg Am. 2001; 83A:S128–
S135. [PubMed: 11314790]
11. Jennissen HP. Accelerated and improved osteointegration of implants biocoated with bone
morphogenetic protein 2 (BMP-2). Ann N Y Acad Sci. 2002; 961:139–142. [PubMed: 12081883]
12. Maus U, Andereya S, Gravius S, Ohnsorge JA, Niedhart C, Siebert CH. BMP-2 incorporated in a
tricalcium phosphate bone substitute enhances bone remodeling in sheep. J Biomater Appl. 2008;
22(6):559–576. [PubMed: 18194994]
13. Peng H, Usas A, Olshanski A, Ho AM, Gearhart B, Cooper GM, et al. VEGF improves, whereas
sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of
angiogenesis. J Bone Miner Res. 2005; 20(11):2017–2027. [PubMed: 16234975]
14. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic
cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat
Med. 1999; 5(6):623–628. [PubMed: 10371499]
15. Samee M, Kasugai S, Kondo H, Ohya K, Shimokawa H, Kuroda S. Bone morphogenetic protein-2
(BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosteal cells
enhances osteoblast differentiation and bone formation. J Pharmacol Sci. 2008; 108(1):18–31.
[PubMed: 18776714]
16. Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth
factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials.
2000; 21(24):2521–2527. [PubMed: 11071602]
17. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone
repair. Eur J Pharm Biopharm. 2004; 58(2):197–208. [PubMed: 15296949]
18. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor
delivery. Nat Biotechnol. 2001; 19(11):1029–1034. [PubMed: 11689847]
19. Nielsen HM, Andreassen TT, Ledet T, Oxlund H. Local injection of TGF-beta increases the
strength of tibial fractures in the rat. Acta Orthop Scand. 1994; 65(1):37–41. [PubMed: 8154281]
Shah et al. Page 11
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
20. Lutolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, et al. Repair of bone
defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol. 2003;
21(5):513–518. [PubMed: 12704396]
21. Saito N, Okada T, Horiuchi H, Ota H, Takahashi J, Murakami N, et al. Local bone formation by
injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers.
Bone. 2003; 32(4):381–386. [PubMed: 12689681]
22. Simmons CA, Alsberg E, Hsiong S, Kim WJ, Mooney DJ. Dual growth factor delivery and
controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow
stromal cells. Bone. 2004; 35(2):562–569. [PubMed: 15268909]
23. Zara J, Siu RK, Zhang X, Shen J, Ngo R, Lee M, et al. High doses of BMP2 induce structurally
abnormal bone and inflammation in vivo. Tissue Eng Part A. 2011; 17(9-10)
24. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading
poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res. 2000; 17(1):100–106. [PubMed:
10714616]
25. Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, Sung MA, et al. Long-term delivery enhances in
vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery.
Biochem Biophys Res Commun. 2008; 369(2):774–780. [PubMed: 18313401]
26. Kokubu T, Hak DJ, Hazelwood SJ, Reddi AH. Development of an atrophic nonunion model and
comparison to a closed healing fracture in rat femur. J Orthop Res. 2003; 21(3):503–510.
[PubMed: 12706024]
27. Eckardt H, Bundgaard KG, Christensen KS, Lind M, Hansen ES, Hvid I. Effects of locally applied
vascular endothelial growth factor (VEGF) and VEGF-inhibitor to the rabbit tibia during
distraction osteogenesis. J Orthop Res. 2003; 21(2):335–340. [PubMed: 12568967]
28. Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors.
Cardiovasc Pathol. 2003; 12(6):295–310. [PubMed: 14630296]
29. Zhang S, Uludag H. Nanoparticulate systems for growth factor delivery. Pharm Res. 2009; 26(7):
1561–1580. [PubMed: 19415467]
30. Decher G. Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science. 1997;
277:1232.
31. Moskowitz JS, Blaisse MR, Samuel RE, Hsu H-P, Harris MB, Martin SD, et al. The effectiveness
of the controlled release of gentamicin from polyelectrolyte multilayers in the treatment of
staphylococcus aureus infection in a rabbit bone model. Biomaterials. 2010; 31:6019–6030.
[PubMed: 20488534]
32. Kim BS, Smith RC, Poon Z, Hammond PT. MAD (multiagent delivery) Nanolayer: delivering
multiple therapeutics from hierarchically assembled surface coatings. Langmuir. 2009; 25(24):
14086–14092. [PubMed: 19630389]
33. Shukla A, Fleming KE, Chuang HF, Chau TM, Loose CR, Stephanopoulos GN, et al. Controlling
the release of peptide antimicrobial agents from surfaces. Biomaterials. 2010; 31(8):2348–2357.
[PubMed: 20004967]
34. Macdonald ML, Rodriguez NM, Shah NJ, Hammond PT. Characterization of tunable FGF-2
releasing polyelectrolyte multilayers. Biomacromolecules. 2010; 11(8):2053–2059. [PubMed:
20690713]
35. Macdonald ML, Samuel RE, Shah NJ, Padera RF, Beben YM, Hammond PT. Tissue integration of
growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. Biomaterials.
2011; 32(5):1446–1453. [PubMed: 21084117]
36. Zelikin AN. Drug releasing polymer thin films: new era of surface-mediated drug delivery. ACS
Nano. 2010; 4(5):2494–2509. [PubMed: 20423067]
37. Facca S, Cortez C, Mendoza-Palomares C, Messadeq N, Dierich A, Johnston APR, et al. Active
multilayered capsules for in vivo bone formation. Proc Natl Acad Sci U S A. 2010; 107(8):3406–
3411. [PubMed: 20160118]
38. Dierich A, Guen E Le, Messaddeq N, Stoltz JF, Netter P, Schaaf P, et al. Bone formation mediated
by synergy-acting growth factors embedded in a polyelectrolyte multilayer film. Adv Mat. Mar;
2007 19(5):693–697.
Shah et al. Page 12
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
39. Pavlukhina S, Lu Y, Patimetha A, Libera M, Sukhishvili S. Polymer multilayers with pH-triggered
release of antibacterial agents. Biomacromolecules. 2010; 11(12):3448–3456. [PubMed:
21028796]
40. Ai H, Jones SA, Lvov YM. Biomedical applications of electrostatic layer-by-layer nano-assembly
of polymers, enzymes, and nanoparticles. Cell Biochem Biophys. 2003; 39(1):23–43. [PubMed:
12835527]
41. Kotov NA, Tang ZY, Wang Y, Podsiadlo P. Biomedical applications of layer-by-layer assembly:
from biomimetics to tissue engineering. Adv Mat. 2006; 18(24):3203–3224.
42. Lynn DM, Langer R. Degradable poly(beta-amino esters): synthesis, characterization, and self-
assembly with plasmid DNA. Journal of the American Chemical Society. 2000; 122:10761–10768.
43. Gregory CA, Gunn WG, Peister A, Prockop DJ. An alizarin red-based assay of mineralization by
adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem.
2004; 329(1):77–84. [PubMed: 15136169]
44. Zhang J, Chua LS, Lynn DM. Multilayered Thin Films that Sustain the Release of Functional DNA
under Physiological Conditions. Langmuir. 2004; 20(19):8015–8021. [PubMed: 15350066]
45. Wood KC, Chuang HF, Batten RD, Lynn DM, Hammond PT. Controlling interlayer diffusion to
achieve sustained, multiagent delivery from layer-by-layer thin films. Proc Natl Acad Sci U S A.
2006; 103(27):10207–10212. [PubMed: 16801543]
46. Kirker KR, Luo Y, Nielson JH, Shelby J, Prestwich GD. Glycosaminoglycan hydrogel films as
bio-interactive dressings for wound healing. Biomaterials. 2002; 23(17):3661–3671. [PubMed:
12109692]
47. Macdonald M, Rodriguez NM, Smith R, Hammond PT. Release of a model protein from
biodegradable self assembled films for surface delivery applications. J Control Release. 2008;
131:228–234. [PubMed: 18721835]
48. Shukla A, Avadhany SN, Fang JC, Hammond PT. Tunable vancomycin releasing surfaces for
biomedical applications. Small. 2010; 6(21):2392–2404. [PubMed: 20925040]
49. Zacharia NS, Modestino M, Hammond PT. Factors influencing the interdiffusion of weak
polycations in multilayers. Macromolecules. 2007; 40(26):9523–9528.
50. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD. Vascular endothelial cell growth
factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF
membrane binding sites. Proc Natl Acad Sci U S A. 1991; 88(13):5819–5823. [PubMed: 1712106]
Shah et al. Page 13
Biomaterials. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Fabrication of polyelectrolyte multilayer films using the layer-by-layer method in a
tetralayer architechture with [Poly2(+)/polyanion(−)/growth factor(+)/polyanion(−)]
depicted below. Four different groups were fabricated. For single growth factor films (A)
rhBMP-2 PEM films with architecture [Poly2/PAA/rhBMP-2/PAA]x, with x = 40, 80, 100,
120 and (B) rhVEGF165 PEM films with architecture [Poly2/CS/rhVEGF165/CS]y, where y
= 20, 30, 40, 50. For dual growth factor films, (C) y = 40 was constant and x = 40, 80, 100,
120. (D) In another formulation, x = 80 was constant and y = 20, 30, 40, 50. The substrate
was always a macroporous polycaprolactone/β-tricalcium phosphate (50wt% PCL/50wt% β-
TCP) waffle cylinder scaffold, with diameter = 10mm and height = 2.5mm.
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Fig. 2.
Polyelectrolyte multilayer films were dipped in a Poly2/anion/growth factor/anion tetralayer
repeat architecture on a macroporous polycaprolactone/β-tricalcium phosphate (50wt%
PCL/50wt% β-TCP) waffle cylinder scaffold. Growth factor loading was controlled by
varying the number of layers dipped on the scaffold. rhBMP-2 released over a period of
about 2 weeks, whereas rhVEGF165 eluted completely within 8 days. 4 groups of films were
fabricated and incubated in 1x PBS at pH 7.4 over 12 days to study growth factor release
from the films. Growth factor release was quantified using ELISA and normalized per
milligram of scaffold. Samples were in triplicate and the error bar is the standard deviation.
Release from (A) Single growth factor rhVEGF165 release and (inset) total rhVEGF165
loading scales linearly with tetralayer number (R2 = 0.96). (B) Single growth factor
rhBMP-2 release and (inset) total rhBMP-2
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Fig. 3.
Pre - osteoblast differentiation assay. Activity of rhBMP-2 released from the polyelectrolyte
multilayer films is preserved. MC3T3-E1 cells were exposed to rhBMP-2 released from
multilayer films, with the dose normalized per milligram of scaffold weight. Alkaline
Phosphatase Assay demonstrates dose dependent early activation of bone differentiation
cascade at Day 5. After 21 days of culture, Alizarin Red Stain confirms the presence of
calcium deposits laid down during the differentiation process. Visual inspection of cultures
after Alizarin red staining confirms a dose dependent presence of calcium deposits. (A, B
and C) Alkaline phosphatase assay at day 3 on cells differentiated with different release
formulations as depicted. (D, E and F) Alizarin red assay at day 14 on cells differentiated
with different release formulation as depicted. Representative images of the alizarin red stain
are below the bar graph in (D, E, F). A single factor ANOVA test allowed rejection of the
null hypothesis for both assays; and a Tukey test between different groups was performed
(s.d., n=9, ** p < 0.01; * p < 0.05; ns = not significant; all others p < 0.001).
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Fig. 4.
Proliferation and Migration assays. Activity of rhVEGF165 released from the polyelectrolyte
multilayer films is preserved. HUVEC cells exposed to rhVEGF165 dose normalized per
milligram of scaffold weight exhibited increased proliferation activity, as measured by
BrdU. (A) 40, 80, 100 and 120 tetralayers of rhBMP-2 followed by 40 tetralayers of
rhVEGF165. (B) 40 tetralayers of rhBMP-2 followed by 20, 30, 40 and 50 tetralayers of
rhVEGF165 and (C) 20, 30, 40 and 50 tetralayers of rhVEGF165. Closure of uniform
“scratched” wound gap was monitored in HUVEC cell cultures over a period of 8 hours.
Cells were fixed and imaged at 20x magnification (D) 40, 80, 100 and 120 tetralayers of
rhBMP-2 followed by 40 tetralayers of rhVEGF165. (E) 40 tetralayers of rhBMP-2 followed
by 20, 30, 40 and 50 tetralayers of rhVEGF165 and (F) 20, 30, 40 and 50 tetralayers of
rhVEGF165. Calcein labeled cells demonstrate charateristics of migrating cells to close the
scratch such as elongated cell bodies in all cases where released rhVEGF165 was part of the
media. A single factor ANOVA test allowed rejection of the null hypothesis for both assays;
and a Tukey test between different groups was performed (s.d., n=9, ** p < 0.01; * p < 0.05;
ns = not significant; all others p < 0.001).
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Fig. 5.
Two dimensional microCT scans (2D) and matched three dimensional reconstructions (3D)
of excised PCL-βTCP half disc scaffolds, which were implanted in the intramuscular region
of rats. Implants were coated with (i) no growth factor, (ii) 6 μg of single growth factor
rhBMP-2 and (iii) 6 μg of single growth factor rhBMP-2 followed by 4μg of rhVEGF165.
The amount of growth factor loaded was determined by fabricating triplicate companion
copies along with the implanted scaffolds, releasing the growth factors in vitro and
performing ELISA detection assays. (Top row) Control scaffolds without growth factors
produce no detectable bone over the duration of the study. Low levels of backscatter is
caused by the polymer. (Middle row) In single growth factor rhBMP-2 films lacking
rhVEGF165, bone formation is restricted to the periphery of the scaffold at 4 weeks and 9
weeks. (Bottom row) As a result of increased vascularity, scaffolds releasing rhVEGF165
demonstrate a smooth, continuous profile in the ectopically formed bone which matures
from 4 weeks to 9 weeks to fill the entire scaffold. In all the images, the bone formed takes
the shape of the scaffold and grows inward when VEGF is present. Images are an isosurface
rendering at 0.25 surface quality factor at a level threshold of 640, as defined by the
proprietary Microview® software from GE Healthcare.
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Fig. 6.
(A) The bone mineral density (BMD) of ectopic bone formed by the rhBMP-2/rhVEGF165
combination scaffolds is 28 ± 4.59% and 32 ± 2.73% higher than bone formed by rhBMP-2
scaffold at 4 and 9 weeks respectively at the periphery of the scaffolds. (B) In the interior,
the BMD for the combination growth factor scaffolds is higher than the single rhBMP-2
scaffolds indicating that more bone is present in the interior, which matures from 4 to 9
weeks as indicated by the increase in BMD. (C) The trabecular thickness of the bone formed
is an important measure of bone maturation, and the trabecular thickness of the bone formed
by the combination scaffolds is about 3 times and 4.5 times that of bone formed by rhBMP-2
scaffolds at 4 and 9 weeks. (s.d., n=9, ** p < 0.01; ns = not significant; all others p < 0.001)
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Fig. 7.
Histology sections from rat femur intramuscular implants. (A to D) Bone is absent in control
scaffolds releasing no growth factors at 4 and 9 weeks verified by (A, C) H&E staining and
(B, D) lack of brilliant blue collagen staining with Masson’s trichrome stain. (A, B) Arrows
indicate pockets where the (PCL/βTCP) polymer scaffold is present at 4 weeks which
degrades over (C, D) 9 weeks, without any bone growth in the vacant space. (E to H) Bone
present in scaffolds releasing single growth factor rhBMP-2. (E) Presence of trabecular bone
with (inset) osteoblasts laying down new bone which is (F) restricted to the periphery of the
scaffold at 4 weeks. Of particular interest is (G) the abundant presence of hematopoietic
cells surrounding the bone in spaces identified as fatty marrow space (asterisk), where (H)
most of the bone formation is restricted to the periphery at 9 weeks and (inset) as bone
matures, it goes from an unorganized collagen matrix structure to a lamellar structure with
aligned collagen fibrils that are birefringent under polarized light. (I to L) Bone present in
scaffolds releasing rhBMP-2 and rhVEGF165. (I) Spicules of trabecular bone which is
present (J) throughout the scaffold as early as 4 weeks. (K) As osteoblasts lay down new
bone, spicules mature into (L) bone that fills up the empty spaces throughout the scaffold as
it degrades with (inset) a greater number of birefringent aligned collagen fibrils present than
fibrils formed when single growth factor rhBMP-2 is released. Bone formed is always
within the scaffold. A, C, E, G, I, K are hematoxylin and eosin (H&E) stains at 10×
objective magnification. B, D, F, H, J, L are Masson’s trichrome stains at 2× objective
magnification. Images in inset are taken at 20× objective magnification.
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